JPMorgan Chase & Co. bought a new stake in MedEquities Realty Trust Inc (NYSE:MRT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,865 shares of the financial services provider’s stock, valued at approximately $118,000.

Several other institutional investors have also bought and sold shares of MRT. Raymond James Financial Services Advisors Inc. bought a new position in shares of MedEquities Realty Trust during the 2nd quarter worth approximately $154,000. Alliancebernstein L.P. bought a new position in shares of MedEquities Realty Trust during the 2nd quarter worth approximately $175,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of MedEquities Realty Trust by 25.1% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,686 shares of the financial services provider’s stock worth $210,000 after buying an additional 3,346 shares in the last quarter. Stevens Capital Management LP bought a new position in shares of MedEquities Realty Trust during the 3rd quarter worth approximately $221,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of MedEquities Realty Trust by 53.9% during the 2nd quarter. Susquehanna International Group LLP now owns 17,723 shares of the financial services provider’s stock worth $224,000 after buying an additional 6,209 shares in the last quarter. Hedge funds and other institutional investors own 92.51% of the company’s stock.

MedEquities Realty Trust Inc (NYSE:MRT) opened at $10.98 on Monday. MedEquities Realty Trust Inc has a twelve month low of $10.06 and a twelve month high of $13.06. The stock has a market capitalization of $348.68, a P/E ratio of 27.45 and a beta of -0.74.

MedEquities Realty Trust (NYSE:MRT) last issued its earnings results on Tuesday, November 7th. The financial services provider reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.13). MedEquities Realty Trust had a return on equity of 5.88% and a net margin of 35.61%. The firm had revenue of $15.77 million for the quarter, compared to analyst estimates of $15.49 million. equities analysts forecast that MedEquities Realty Trust Inc will post 1.12 EPS for the current year.

In other news, Director Randy L. Churchey bought 5,300 shares of the stock in a transaction dated Monday, November 20th. The shares were bought at an average cost of $10.87 per share, with a total value of $57,611.00. Following the completion of the transaction, the director now directly owns 46,776 shares of the company’s stock, valued at $508,455.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John W. Mcroberts bought 18,000 shares of the stock in a transaction dated Friday, November 17th. The shares were purchased at an average cost of $10.74 per share, for a total transaction of $193,320.00. The disclosure for this purchase can be found here. Insiders have bought 23,600 shares of company stock worth $254,129 over the last ninety days. 2.50% of the stock is owned by insiders.

A number of equities analysts have issued reports on MRT shares. KeyCorp restated a “buy” rating and set a $13.00 price target on shares of MedEquities Realty Trust in a report on Tuesday, September 26th. Capital One Financial started coverage on MedEquities Realty Trust in a report on Monday, October 23rd. They set an “equal weight” rating and a $13.00 price target on the stock. B. Riley restated a “buy” rating on shares of MedEquities Realty Trust in a report on Wednesday, November 1st. Zacks Investment Research upgraded MedEquities Realty Trust from a “sell” rating to a “hold” rating and set a $12.00 price target on the stock in a report on Wednesday, November 15th. Finally, ValuEngine upgraded MedEquities Realty Trust from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.00.

TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Invests $118,000 in MedEquities Realty Trust Inc (MRT) Stock” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/01/22/jpmorgan-chase-co-invests-118000-in-medequities-realty-trust-inc-mrt-stock.html.

About MedEquities Realty Trust

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

Want to see what other hedge funds are holding MRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MedEquities Realty Trust Inc (NYSE:MRT).

Institutional Ownership by Quarter for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.